Literature DB >> 10780525

Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms.

S Munakata1, T Enomoto, M Tsujimoto, Y Otsuki, H Miwa, H Kanno, K Aozasa.   

Abstract

Expression of apoptosis-related proteins, bcl-2, Bax, Fas and Fas ligand (L), in ovarian epithelial neoplasms together with its clinical relevance was examined by immunohistochemistry. They included 36 cases with adenoma, 33 with low potential malignancy (LPM) and 63 with carcinomas. bcl-2 expression was observed in 14 of 36 cases (39%) with adenoma, five of 33 (15%) with LPM (P< 0.05) and 12 of 63 (19%) with carcinoma (P < 0.05). Cases with bcl-2 expression showed more favourable prognosis than those without, but the difference was not statistically significant. There was no difference in frequency of Bax and Fas expression between each histologic category. Fas L expression was observed in one of 36 cases (3%) with adenoma, but in 12 of 33 (36%) with LPM (P < 0.001) and 42 of 63 (67%) with carcinoma (P < 0.0001). In carcinomas, cases expressing Fas L showed a less favourable prognosis than those without (P = 0.02). Density of CD8+ lymphocytes, possibly cytotoxic T-cells, was higher in serous carcinoma with negative Fas L expression than those with positive Fas L expression. These findings suggest that Fas L expressing carcinomas induce apoptosis in infiltrating CTL with Fas expression, and escape from immune surveillance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10780525      PMCID: PMC2363379          DOI: 10.1054/bjoc.1999.1073

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.

Authors:  Z N Oltvai; C L Milliman; S J Korsmeyer
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

2.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

3.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.

Authors:  D Hockenbery; G Nuñez; C Milliman; R D Schreiber; S J Korsmeyer
Journal:  Nature       Date:  1990-11-22       Impact factor: 49.962

4.  Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms.

Authors:  R Henriksen; K Funa; E Wilander; T Bäckström; M Ridderheim; K Oberg
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

5.  Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.

Authors:  G A Omura; M F Brady; H D Homesley; E Yordan; F J Major; H J Buchsbaum; R C Park
Journal:  J Clin Oncol       Date:  1991-07       Impact factor: 44.544

6.  bcl-2 protein in non-small-cell lung carcinoma.

Authors:  F Pezzella; H Turley; I Kuzu; M F Tungekar; M S Dunnill; C B Pierce; A Harris; K C Gatter; D Y Mason
Journal:  N Engl J Med       Date:  1993-09-02       Impact factor: 91.245

7.  Immunohistochemical analysis of bcl-2, bax, mcl-1, and bcl-X expression in ovarian surface epithelial tumors.

Authors:  B M Wehrli; S Krajewski; R D Gascoyne; J C Reed; C B Gilks
Journal:  Int J Gynecol Pathol       Date:  1998-07       Impact factor: 2.762

8.  bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation.

Authors:  T J McDonnell; N Deane; F M Platt; G Nunez; U Jaeger; J P McKearn; S J Korsmeyer
Journal:  Cell       Date:  1989-04-07       Impact factor: 41.582

Review 9.  Relative frequency of primary ovarian neoplasms: a 10-year review.

Authors:  P P Koonings; K Campbell; D R Mishell; D A Grimes
Journal:  Obstet Gynecol       Date:  1989-12       Impact factor: 7.661

10.  Epidemiologic pathology of ovarian tumors: a histopathologic review of primary ovarian neoplasms diagnosed in the Denver Standard Metropolitan Statistical Area, 1 July-31 December 1969 and 1 July-31 December 1979.

Authors:  Y Katsube; J W Berg; S G Silverberg
Journal:  Int J Gynecol Pathol       Date:  1982       Impact factor: 2.762

View more
  13 in total

Review 1.  Fas ligand and the fate of antitumour cytotoxic T lymphocytes.

Authors:  Joe O'Connell
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

2.  Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.

Authors:  Eiman Adel Hasby
Journal:  Pathol Oncol Res       Date:  2011-12-08       Impact factor: 3.201

3.  Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma.

Authors:  Samaneh Boroumand-Noughabi; Hamid Reza Sima; Kamran Ghaffarzadehgan; Mostafa Jafarzadeh; Hamid Reza Raziee; Hanieh Hosseinnezhad; Omeed Moaven; Mohammad Taghi Rajabi-Mashhadi; Amir Abbas Azarian; Mojtaba Mashhadinejad; Jalil Tavakkol-Afshari
Journal:  BMC Cancer       Date:  2010-06-10       Impact factor: 4.430

4.  Differential expression of Fas family members and Bcl-2 family members in benign versus malignant epithelial ovarian cancer (EOC) in North Indian population.

Authors:  Parvesh Chaudhry; Radhika Srinivasan; Firuza D Patel
Journal:  Mol Cell Biochem       Date:  2012-06-12       Impact factor: 3.396

5.  Corticotropin-releasing hormone (CRH) is expressed in the human cervical carcinoma cells (HeLa) and upregulates the expression of Fas ligand.

Authors:  Eirini Taliouri; Thomas Vrekoussis; Aikaterini Vergetaki; Theodore Agorastos; Antonis Makrigiannakis
Journal:  Tumour Biol       Date:  2012-10-18

6.  Serum sFas and tumor tissue FasL negatively correlated with survival in Egyptian patients suffering from breast ductal carcinoma.

Authors:  Ashgan I El-Sarha; Gehan M Magour; Sameh M Zaki; Mohamed Y El-Sammak
Journal:  Pathol Oncol Res       Date:  2008-11-18       Impact factor: 3.201

7.  Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.

Authors:  Giovanna Andreola; Licia Rivoltini; Chiara Castelli; Veronica Huber; Paola Perego; Paola Deho; Paola Squarcina; Paola Accornero; Francesco Lozupone; Luana Lugini; Annarita Stringaro; Agnese Molinari; Giuseppe Arancia; Massimo Gentile; Giorgio Parmiani; Stefano Fais
Journal:  J Exp Med       Date:  2002-05-20       Impact factor: 14.307

8.  Circulating soluble Fas levels and risk of ovarian cancer.

Authors:  Arslan Akhmedkhanov; Eva Lundin; Seth Guller; Annekatrin Lukanova; Andrea Micheli; Yuehong Ma; Yelena Afanasyeva; Anne Zeleniuch-Jacquotte; Vittorio Krogh; Per Lenner; Paola Muti; Sabina Rinaldi; Rudolf Kaaks; Franco Berrino; Göran Hallmans; Paolo Toniolo
Journal:  BMC Cancer       Date:  2003-12-22       Impact factor: 4.430

9.  Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation.

Authors:  V Minas; A Rolaki; S N Kalantaridou; J Sidiropoulos; S Mitrou; G Petsas; U Jeschke; E A Paraskevaidis; G Fountzilas; G P Chrousos; N Pavlidis; A Makrigiannakis
Journal:  Br J Cancer       Date:  2007-07-31       Impact factor: 7.640

10.  A study on evaluation of apoptosis and expression of bcl-2-related marker in wound healing of streptozotocin-induced diabetic rats.

Authors:  Surya Bhan; Rahul Mitra; A K Arya; H P Pandey; K Tripathi
Journal:  ISRN Dermatol       Date:  2013-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.